Introduzca una acción o criptomoneda en el cuadro de búsqueda para obtener un resumen
Novo Nordisk A/S
NOVANovo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark. Address: Novo Alle 1, Bagsvaerd, Denmark, 2880
Analytics
Precio Objetivo de WallStreet
148.23 USDRelación P/E
43.5503Rentabilidad por dividendo
1.11 %Año en curso
Año anterior
Trimestre actual
Último trimestre
Año en curso
Año anterior
Trimestre actual
Último trimestre
Cifras clave NOVA
Análisis de dividendos NOVA
Aumento del dividendo durante 5 años
62 %Crecimiento continuo
5 añosRatio de pago medio en 5 años
19 %Tendencia del payout NOVA
Valoración de la acción NOVA
Finanzas NOVA
Realice un seguimiento de las métricas clave de cada acción en un solo lugar y sin complicaciones
Hazte premiumResultados | 2019 | Dinámica |